Fecal Immunochemical Test

Defensive strategies, such as denying immediacy of testing or exempting oneself, are key barriers to at-home colorectal cancer screening, according to study results published in Cancer.

Data showed that colorectal cancer screening delays of 1 to 2 years because of the COVID-19 pandemic had minimal impact on individuals aged 50 to 60 years, whereas these delays had pronounced impact on those aged 65 years and older.

A risk-adapted approach for population-based colorectal cancer screening was a viable and cost-effective option compared with existing colonoscopy and fecal immunochemical test strategies, according to new research in China.

Regardless of patient sex or BMI, initiating colorectal cancer screening with colonoscopy at age 45 years or with fecal immunochemical testing at age 40 years was cost-effective, according to new research.

Researchers have identified higher rates of young-onset colorectal cancer mortality among patients in the Midwest and Great Lakes regions.

The Association of Coloproctology of Great Britain and Ireland and the British Society of Gastroenterology have published a joint guideline for the strategic use of fecal immunochemical testing in people with suspected colorectal cancer.

Colorectal cancer screening prevalence remained low in 2018 among U.S. adults aged 50 to 54 years vs. 70 to 75 years, with the younger group exhibiting larger disparities by race/ethnicity, education level, income and insurance.

SAN DIEGO — Pre-alert text message notification followed by mailed fecal immunochemical test kits improved population-level screening for colorectal cancer during COVID-19, according to research.

In a Healio video exclusive, Subhankar Chakraborty, MD, PhD, a gastroenterologist at The Ohio State University Wexner Medical Center, outlines a new initiative that aims to cut colorectal cancer screening disparities in half by 2023.

This award goes to a product that stands out as a major disruption to the practice of gastroenterology.